![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 2 of 2. This is the beginning of the thread.
Posted by jlbl2l on March 31, 2004, at 10:00:37
Pfizer's LYRICA Receives Positive Opinion in Europe from Committee for Proprietary Medicinal Products
NEW YORK, March 25, 2004 -- Pfizer Inc said today that the Committee for Proprietary Medicinal Products (CPMP) adopted a positive opinion recommending marketing authorization of LYRICA® (pregabalin) in the European Union for the treatment of neuropathic pain and add-on therapy for partial seizures.Following the CPMP's positive opinion, their recommendation will be reviewed by the European Commission (EC), which has authority to grant marketing authorizations for the European Union. Pfizer anticipates a final decision from the EC in June 2004.
Developed by Pfizer, pregabalin has a novel mechanism of action which allows treatment of certain neurologic and psychiatric disorders.
“We are pleased with the CPMP’s positive opinion of LYRICA and expect that marketing authorization will be granted by the European Commission,” said Dr. Joseph Feczko, president of Worldwide Development at Pfizer. “LYRICA will be a new treatment option for neuropathic pain, which is a debilitating form of chronic pain that affects millions of Europeans. In addition, LYRICA will benefit patients suffering from epilepsy by providing better control of their seizures.”
Neuropathic pain, often characterized by a burning, tingling and/or shock-like sensation, is a type of chronic pain that is often misdiagnosed, under-treated, and a significant burden to sufferers, their families, and society. Epilepsy, a chronic neurological condition that is marked by seizures, affects an estimated 50 million people worldwide. Treatment that effectively controls or reduces the frequency of seizures has important consequences not only on the physical well-being and productivity of patients but also their quality of life.
Pregabalin is currently under review by the U.S. Food and Drug Administration for the management of neuropathic pain associated with diabetic peripheral neuropathy and herpes zoster (postherpetic neuralgia), as adjunctive therapy in the treatment of partial seizures, and for the treatment of generalized anxiety disorder in adults.
Though there are no comprehensive figures estimating the costs associated with neuropathic pain, the condition contributes significantly to direct healthcare costs and indirect costs such as worker productivity and absenteeism.
Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world's best-known consumer products.
Posted by pseudonym on March 31, 2004, at 20:55:25
In reply to Pregabalin - Lyrica - June 2004 in Europe, posted by jlbl2l on March 31, 2004, at 10:00:37
This is exciting news. People who have been suffering from anxiety will now have another tool in their arsenal. I'm just hopeful it will help eliminate social anxiety.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.